PAVmed (PAVM) AI Stock Analysis

• Market Cap: $10.96M
• Dividend Yield: N/A
• Average Volume (3M): 377.79K
• Price to Earnings (P/E): 0.4
• Beta (1Y): 1.30
• Revenue Growth: -73.36%
• EPS Growth: N/A
• Country: US
• Employees: 39
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.74
• Shares Outstanding: 21,610,516
• 10 Day Avg. Volume: 774,204
• 30 Day Avg. Volume: 377,786
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 3.16
• Enterprise Value/Revenue: 4.94
• Enterprise Value/Gross Profit: -0.98
• Enterprise Value/Ebitda: >-0.01
• 1Y Price Target: $11.00
• Price Target Upside: 2458.14% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 42 Neutral
• Price Target: $0.50 ▲(16.28% Upside)

The overall stock score for PAVmed is primarily influenced by its poor financial performance, characterized by significant profitability and cash flow challenges. Technical analysis suggests weak momentum, while the valuation indicates potential risks despite a low P/E ratio. The absence of earnings call insights and corporate events further limits positive factors.

Positive Factors

Innovative Product Portfolio

PAVmed's focus on innovative medical devices like EsoCheck and CarpX positions it well to meet unmet clinical needs, supporting long-term growth.

Revenue Model

The direct sales and distribution agreements enable PAVmed to reach a wide range of customers, potentially enhancing revenue stability and growth.

Free Cash Flow Growth

Strong free cash flow growth indicates improved cash generation ability, which is crucial for funding operations and future investments.

Negative Factors

Negative Profit Margins

Severe negative profit margins suggest operational inefficiencies, impacting the company's ability to convert revenue into profit.

Liquidity Challenges

Negative operating cash flow coverage indicates liquidity challenges, potentially limiting PAVmed's ability to meet short-term obligations.

Negative Return on Equity

A deeply negative ROE reflects significant losses relative to shareholder equity, raising concerns about long-term shareholder value.

PAVmed Business Overview & Revenue Model

Company Description

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

How the Company Makes Money

PAVmed generates revenue through the sales of its medical devices and diagnostic products to hospitals, clinics, and healthcare providers. The company's revenue model is primarily based on direct sales and distribution agreements, allowing it to reach a wide range of customers. Key revenue streams include product sales from its innovative devices, potential licensing agreements, and partnerships with healthcare organizations that facilitate the adoption of its technologies. Additionally, PAVmed may benefit from reimbursement policies for its products, which can enhance sales and overall revenue growth.

PAVmed Financial Statement Overview

Summary

PAVmed faces significant financial challenges, particularly in terms of profitability and cash flow management. Despite revenue growth, the company struggles with negative margins and returns, indicating operational inefficiencies and potential liquidity risks.

Income Statement

PAVmed's income statement reveals significant challenges. The company has experienced substantial negative margins across all key metrics, including gross profit, net profit, EBIT, and EBITDA. Despite a notable revenue growth rate of 251.93% in the TTM period, the negative margins indicate severe profitability issues, with a net profit margin of -1885.26% and a gross profit margin of -5.06%. These figures suggest that the company is struggling to convert its revenue into profit, highlighting a critical need for operational improvements.

Balance Sheet

The balance sheet shows a mixed picture. While the debt-to-equity ratio is relatively low at 0.25, indicating manageable leverage, the return on equity is deeply negative at -140.79%, reflecting significant losses relative to shareholder equity. The equity ratio stands at 85.47%, suggesting a strong equity base relative to total assets. However, the negative ROE and historical equity deficits raise concerns about the company's ability to generate returns for shareholders.

Cash Flow

PAVmed's cash flow statement indicates some positive trends, such as a free cash flow growth rate of 72.83% in the TTM period. However, the operating cash flow to net income ratio is negative, and the free cash flow to net income ratio is slightly above 1, suggesting that the company is not effectively converting its net income into cash flow. The negative operating cash flow coverage ratio further underscores liquidity challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.01M	3.00M	2.45M	377.00K	500.00K	0.00
Gross Profit	-35.49M	-3.04M	-3.97M	-3.24M	-85.00K	-23.00K
EBITDA	-4.63B	29.67M	-75.74M	-99.41M	-55.90M	-35.81M
Net Income	72.88M	39.79M	-64.17M	-88.98M	-50.35M	-34.33M
Balance Sheet
Total Assets	43.89M	30.66M	33.12M	53.98M	86.98M	19.78M
Cash, Cash Equivalents and Short-Term Investments	4.00B	1.19M	19.64M	39.74M	77.26M	17.26M
Total Debt	9.31B	31.86M	48.73M	36.64M	0.00	14.96M
Total Liabilities	12.47M	37.69M	57.14M	43.05M	7.56M	20.25M
Stockholders Equity	40.79M	-2.50M	-53.83M	-9.68M	61.67M	1.90M
Cash Flow
Free Cash Flow	-2.77B	-33.61M	-52.28M	-72.53M	-42.06M	-21.97M
Operating Cash Flow	-2.77B	-33.55M	-52.04M	-70.98M	-40.59M	-21.91M
Investing Cash Flow	-24.14M	-16.18M	758.00K	-4.74M	-3.72M	-55.00K
Financing Cash Flow	2.49B	31.28M	31.17M	38.21M	104.31M	33.01M

PAVmed Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.43
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PAVM, the sentiment is Negative. The current price of 0.43 is below the 20-day moving average (MA) of 0.47, below the 50-day MA of 0.46, and below the 200-day MA of 0.60, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 41.34 is Neutral, neither overbought nor oversold. The STOCH value of 24.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PAVM.

PAVmed Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TNON	47 Neutral	$11.01M	―	-335.48%	―	-12.60%	95.87%
HSCS	45 Neutral	$9.11M	―	-193.24%	―	-66.40%	65.99%
BMRA	44 Neutral	$8.95M	―	-69.61%	―	-11.31%	47.64%
CODX	44 Neutral	$16.65M	―	-63.40%	―	-91.14%	9.47%
PAVM	42 Neutral	$10.96M	0.44	―	―	-73.36%	―
SSKN	41 Neutral	$10.74M	―	-235.41%	―	0.36%	-17.20%

PAVmed Corporate Events

PAVmed’s Lucid Diagnostics Completes Public Stock Offering

On September 11, 2025, Lucid Diagnostics Inc., a subsidiary of PAVmed Inc., completed a public offering of 28,750,000 shares of its common stock at $1.00 per share, raising approximately $26.9 million after expenses. The proceeds from this offering are intended for working capital and general corporate purposes, potentially impacting the company’s operational capabilities and market positioning.

The most recent analyst rating on (PAVM) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.

PAVmed Reports Q2 2025 Financial Results and Developments

In its second quarter of 2025, PAVmed Inc. reported significant business developments and financial results. Lucid Diagnostics processed 2,756 EsoGuard tests, generating $1.2 million in revenue, and secured a Medicare LCD meeting for September 4, 2025. Veris Health completed financing and is advancing its implantable monitor towards FDA clearance, with strategic partnerships in place to enhance its commercial deployment. PAVmed’s financial results showed a GAAP net loss of $13.3 million, with a strengthened balance sheet and cash reserves of $4.0 million as of June 30, 2025.

The most recent analyst rating on (PAVM) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.

Lucid Diagnostics Reports Q2 2025 Financial Results

Lucid Diagnostics Inc., a subsidiary of PAVmed Inc., is a commercial-stage medical diagnostics company focused on cancer prevention, particularly targeting patients with GERD at risk of developing esophageal precancer and cancer. The company utilizes its EsoGuard Esophageal DNA Test, a noninvasive tool designed for early detection of esophageal precancer.

PAVmed Granted Nasdaq Extension for Compliance

On July 29, 2025, PAVmed Inc. received a notification from Nasdaq granting an additional 180 days, until January 19, 2026, to comply with the minimum bid price requirement of $1 per share. The company had initially been given until July 22, 2025, to meet this requirement but failed to do so. Despite this, Nasdaq has allowed an extension, and PAVmed plans to explore all options to regain compliance. The company’s stock will continue to trade under the symbol ‘PAVM’ without interruption.

The most recent analyst rating on (PAVM) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.